< Zurück zu den aktuellen Neuigkeiten & Events

Blogs

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Oktober 2025

  • Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it?

This case centres on the evidence required to establish “serious doubts” regarding novelty of the well-known Cripps Pink (“Pink Lady”) and Cripps Red (“Sundowner”) apple varieties. As a reminder, novelty of a plant variety right is assessed using a test of “commercial novelty”, rather than a test of “absolute novelty” as used in patent law.

The EU General Court decision (T-159/24) reaffirms that implicit consent to commercialise a plant variety can undermine its EU plant variety right (CPVR) protection.  The Court decided that the supply of varieties to nurseries without clear restrictions as regards their use long before filing the CPVR applications was enough to provide implicit consent to exploit them commercially, to the detriment of their EU plant variety rights.

The takeaway? Even if the intention is merely to hand out new varieties for testing purposes in commercially relevant field trials, it is best to expressly limit the use of new varieties for testing or research purposes to preserve their novelty in a subsequent CPVR application.

The Court also addressed the role of declarations as evidence. It confirmed that declarations may carry weight even without supporting documentation, provided they’re credible, made by impartial parties, and consistent with other evidence.

In short, record-keeping and express limitations regarding commercial uses in contracts are key. Creators of new varieties should document when varieties are disposed of and retain evidence of any use restrictions placed on those varieties to mitigate the possibility of a third party establishing “serious doubts” regarding the novelty of the variety.

Click the button below to read our full article.

Aktuelle Neuigkeiten

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Weiterlesen

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Weiterlesen

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Weiterlesen
Event - 5. November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Veranstaltungsdetails

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Weiterlesen

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Weiterlesen
Event - 14. Oktober 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Veranstaltungsdetails

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Weiterlesen